Keith Halverstam is a partner at Latham & Watkins, where he is Co-Chair of the New York Corporate Department. His practice focuses on capital markets transactions and public company representation. He also regularly leads large cross-disciplinary Latham teams in connection with public company crisis management mandates, including with respect to restatements and SEC investigations.
Mr. Halverstam’s broad range of clients includes large Fortune 250 corporations, newly public technology and life sciences companies, and major investment banks. During his career, Mr. Halverstam has represented issuers and underwriters on more than 500 capital markets transactions with an aggregate market value of hundreds of billions of dollars.
Mr. Halverstam is experienced in a broad range of financing transactions, including:
- Initial public offerings
- Secondary and follow-on equity offerings
- Secured and unsecured high-yield offerings
- Debt commitment letters
- Leveraged buyout financings
Prior to joining Latham, Mr. Halverstam clerked for Judge Frank H. Easterbrook on the US Court of Appeals for the 7th Circuit.
Mr. Halverstam’s recent clients include:
- BioXcel Therapeutics
- BofA Merrill Lynch
- Cardiac Science Corporation
- Cognizant Technology Solutions
- Credit Suisse
- Deutsche Bank
- J.P. Morgan
- Macquarie Capital (USA)
- QVT Funds
- Royal Bank of Canada
- Shuffle Master
- Syneos Health
- Vista Aviation